June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Ref-1 is overexpressed in murine retinal neovascularization and localizes with nuclei of multiple retinal cell types
Author Affiliations & Notes
  • Gabriella Hartman
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Anbukkarasi Muniyandi
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Mark R Kelley
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Timothy William Corson
    Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Gabriella Hartman None; Anbukkarasi Muniyandi None; Mark Kelley Ocuphire Pharma, Code C (Consultant/Contractor), Apexian Pharmaceutical, Code C (Consultant/Contractor), US 16/968,009, Code P (Patent); Timothy Corson US 16/968,009, Code P (Patent)
  • Footnotes
    Support  NIH/NEI R01EY031939; Research to Prevent Blindness (RPB)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1249. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gabriella Hartman, Anbukkarasi Muniyandi, Mark R Kelley, Timothy William Corson; Ref-1 is overexpressed in murine retinal neovascularization and localizes with nuclei of multiple retinal cell types. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1249.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti-vascular endothelial growth factor intravitreal injections are the current mainstay treatments for retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR), but lack of universal response creates a need to identify new therapeutic targets. One promising target is the redox function of APE1/Ref-1, a bifunctional protein that regulates transcription factors implicated in neovascular eye diseases. We previously demonstrated an increase of Ref-1 expression in the oxygen-induced retinopathy (OIR) mouse model, but the expression of Ref-1 in other mouse models of retinal neovascularization and cell-type localization is unknown. Here, we aimed to assess Ref-1 expression in the Vldlr knock-out (VKO) genetic mouse model of subretinal neovascularization and Ref-1’s cell-type localization in OIR.

Methods : VKO and wild-type mice underwent optical coherence tomography (OCT), fundus imaging, and fluorescein angiography (FA) before euthanasia at P14, P21, P28, 8 weeks, 3 months, and 6 months old, with pimonidazole injection 2 hours before euthanasia. Retinal and choroidal flatmounts were coimmunostained for Ref-1, vasculature (isolectin B4), and Hypoxyprobe to detect hypoxia via pimonidazole adducts. For OIR, neonatal mice and dams were exposed to hyperoxia (75% O2) or room air for 5 days (P7-P12), with enucleation at P12, P15, and P17. Frozen sections were coimmunostained for Ref-1, isolectin B4, RPE65 (RPE), cone arrestin (cones), rhodopsin (rods), vimentin (Müller glia), and Brn3a (retinal ganglion cells).

Results : Ref-1 was overexpressed in the VKO mouse model compared to wild-type and colocalized with neovessels. OCT, fundus, and FA revealed that increased Ref-1 expression was associated with development of neovascularization. Mean fluorescence intensity of Ref-1 in VKO eyes was higher compared to age-matched control eyes (p<0.0001, n=8-18, t-test). In OIR, Ref-1 colocalized with endothelial cells and the nuclei of cones, horizontal cells, and retinal ganglion cells.

Conclusions : Ref-1 is highly expressed in angiogenic tufts in the murine VKO and OIR models, suggesting a role for Ref-1 in retinal neovascularization. Ref-1 colocalizes with the nuclei of several cell types in both healthy and diseased eyes, suggesting regulation of DNA damage and oxidative stress. These results provide context for this potential therapeutic target for PDR and/or ROP.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×